Why Partner with STCC

The Singapore Translational Cancer Consortium (STCC) is a nationally coordinated oncology platform that brings together Singapore's leading cancer centres, healthcare clusters, universities and research institutes to accelerate cancer research, translational science and clinical innovation.

As a single point of access to Singapore's oncology ecosystem, STCC enables industry partners, researchers, clinicians and innovators to collaborate across the full cancer research continuum, from discovery and translational research to investigator-initiated studies, clinical trials, real-world evidence generation and health policy impact.

Our Capabilities

Why Organisations Choose STCC

STCC serves as a single gateway into Singapore's oncology research ecosystem, bringing together leading cancer research, clinical care, translational science, data, tissue, and innovation capabilities through one coordinated national platform.

Instead of navigating multiple organisations independently, partners can access:

• Clinical trial and investigational medicine expertise

• National-scale cancer datasets and biospecimen resources

• Translational research and biomarker development capabilities

• Population health, health economics and real-world evidence programmes

• Artificial intelligence and multi-modal oncology data initiatives

• Multidisciplinary clinical and scientific experts across major cancer indications

STCC collaborates with academic researchers and clinical investigators, biopharmaceutical and biotechnology companies, and healthcare institutions to advance cancer research, translational science, clinical innovation, and population health impact. By providing a single point of contact for collaboration, STCC reduces operational complexity, accelerates study initiation, and enables seamless access to Singapore's integrated oncology ecosystem.